00 / Clinical protocol intelligenceInvestor pitch · 2026
One protocol.
Every stakeholder.
Zero translation loss.
Trialign is the AI-native protocol intelligence layer for sponsors, CROs, labs and sites. Ingest the protocol once — generate synchronized, role-specific outputs for everyone downstream, automatically kept current through every amendment.
Protocol · v3.2live
ONC-2026-014 · Phase II
Amendment 3 detected — 2 min ago
Site SOP · V04 Wk-8
12 sites
01 / The problemManual re-interpretation, at every handoff
One protocol,
five re-interpretations.
Every clinical trial runs on a single source of truth. But that protocol is manually re-read, re-typed and re-interpreted at every handoff — by staff with different training and disconnected tools.
Handoff 01
Sponsor
Authors protocol
re-read · re-typed · re-interpreted
Handoff 02
CRO
Operationalizes plan
re-read · re-typed · re-interpreted
Handoff 03
Lab vendor
Builds spec kits
re-read · re-typed · re-interpreted
Handoff 04
Site / PI
Executes visits
re-read · re-typed · re-interpreted
Handoff 05
Ancillary vendors
Interpret again
re-read · re-typed · re-interpreted
The result: manual re-entry, inconsistent scientific interpretation, no shared data model, and version drift the moment the protocol is amended — driving delay, cost overrun and data quality risk across the entire trial.
02 / Why it mattersThe cost of manual re-interpretation
76%
of Phase I–IV protocols now require at least one substantial amendment — up from 57% in 2015
$141K–$535K
median direct cost to implement a single substantial amendment (Phase II vs. III)
260 days
average time from amendment approval to full ethics-committee rollout across sites
~$800K / day
in unrealized commercial value while a trial sits delayed, on top of direct burn
Source: Tufts Center for the Study of Drug Development (Tufts CSDD), 2023–2024 analyses
03 / Why nowFour converging forces
The window
is opening.
01
AI can finally read a protocol
LLMs now extract structured meaning — endpoints, visit schedules, eligibility, lab specs — from dense scientific text at expert-level accuracy.
02
Regulatory push for interoperability
CDISC, FHIR and eSource mandates are pushing sponsors and sites toward shared, structured data models instead of PDFs and email.
03
Trials are more global, more complex
Decentralized and multi-country studies multiply the number of handoffs — and the cost of every re-interpretation error.
04
Clinical ops talent is stretched thin
Experienced CRAs, CTAs and study start-up staff are scarce; manual reconciliation doesn't scale with demand.
04 / The solutionTrialign · the protocol intelligence layer
Ingest the protocol once. Synchronize everyone.
Role-specific outputs for every stakeholder — automatically generated, automatically kept current through every amendment.
- Digital twin of the protocol
- Live diff on every amendment
- Human review & sign-off
05 / How it worksFrom PDF to synchronized ops · in minutes
Weeks of manual handoffs, compressed to hours.
1
Upload the protocol (any version). NLP/LLM extraction pulls endpoints, visit schedules, eligibility, lab and imaging specs.
2
Extracted data populates a protocol knowledge graph — the single, versioned source of scientific truth.
3
Role-specific artifacts produced instantly: lab manuals, site SOPs, monitoring plans, CRO build checklists.
4
On amendment, Trialign diffs the protocol and auto-flags every downstream artifact and stakeholder affected.
5
Human experts review, approve and publish — keeping accountability while removing manual re-transcription.
No new data entry for staff. Trialign layers on top of existing eTMF, CTMS and EDC systems — it reads and writes to them, rather than replacing them.
06 / Product in actionBefore / after
Today — manual
4–8 weeks to alignment
- Study team manually reads full protocol PDF
- Each function re-derives its own version of requirements
- Lab specs, site SOPs, CRF built in parallel silos
- Inconsistencies surface late — often after activation
- Amendments trigger a full manual re-work cycle
With Trialign
Hours to same-day sync
- Protocol uploaded once — parsed into a knowledge graph
- Every function pulls from the same synchronized source
- Lab manuals, site SOPs, monitoring plans auto-generated
- Conflicts flagged and resolved before site activation
- Amendments auto-propagate; teams review a targeted diff
07 / Business modelFour revenue streams, one data layer
R1
Platform subscription
Annual SaaS fee per active protocol / trial, sold to sponsors and CROs. Core recurring revenue.
R2
Site network licensing
Per-seat access for site coordinators and PIs to receive auto-generated, always-current SOPs.
R3
Vendor integration fees
Usage-based API fees for lab, imaging and ancillary vendors connecting into the protocol graph.
R4
Change-mgmt & insights
Premium amendment-impact module plus anonymized cross-trial benchmarking, sold as an add-on.
Land-and-expand: start with one sponsor study team, expand to their CRO and site network, then monetize the resulting data graph across every future trial.
08 / MarketA fast-growing market, ripe for AI disruption
TAM
$15.8B – $31B
Global eClinical · 2026–2031 · 14.7% CAGR
SAM
~$3B
Protocol / study start-up + CTMS
$2–3B/year in avoidable amendment cost.
Protocol amendments alone represent a $2–3B/year avoidable-cost pool across active global trials — a wedge Trialign directly targets.
09 / RoadmapShort-term focus, long-term platform
0–6 mo
Design partners
- —Sign 3 mid-size biotech sponsors
- —Ship protocol ingestion + lab spec auto-generation
- —Validate accuracy vs. manual gold-standard
6–18 mo
Commercial launch
- —GA platform subscription for sponsors & CROs
- —Site network module + CRO ops checklist generator
- —First paid vendor integrations (2 central labs)
18–36 mo
Network expansion
- —Amendment change-mgmt at scale
- —Multi-country / multi-language protocol support
- —Expand to 25+ sponsors, 10+ CROs, 500+ sites
3–5 yr
Data platform
- —Cross-trial benchmarking & predictive analytics
- —Default protocol interoperability layer
- —Category leadership in AI-native clinical ops
10 / Why we winNot another eClinical point solution
The protocol drives the system — not the other way around.
| Legacy CTMS / eTMF | Point-AI tools | Trialign |
|---|
| Single source of scientific truth | ✕ | ✕ | ✓ |
| Auto-propagates protocol amendments | ✕ | △ | ✓ |
| Role-specific outputs for every stakeholder | △ | ✕ | ✓ |
| Works across sponsor, CRO, lab & site | △ | ✕ | ✓ |
| Built protocol-first, not form-first | ✕ | △ | ✓ |
11 / The askRaising $4M seed to commercial launch
$4M seed
to reach GA.
Funds take us from validated design partners to a GA platform live across sponsors, CROs and site networks.
EngineeringProtocol NLP pipeline, knowledge graph, integrations
55%Clinical & GTMClinical ops experts, design-partner success, sales
30%Compliance & infra21 CFR Part 11, GxP validation, security & hosting
15%The vision
"Every clinical trial runs on a protocol that understands itself — where scientific intent, once written, flows to every stakeholder without loss, delay, or manual translation."